Similar Search Results

Does Regulation Drive International Research Cooperation? Evidence from the Pharmaceutical Sector

Bennato, Anna Rita - 2019

To what extent is an increased stringency of the Intellectual Property Rights (IPR) system apt to stimulate research cooperation between developed and emerging economies? To address this question, we empirically investigate how international joint research projects in the pharmaceutical sector...

Persistent link: https://www.econbiz.de/10012895510

Advertising Regulations in Pharmaceutical Markets : Product versus Enlightenment

Ishida, Junichiro - 2019

This paper analyzes the optimal content regulation of direct-to-consumer advertisement (DTCA) in a pharmaceutical … typical subjective symptoms under enlightenment DTCA. The content regulation changes the nature of market competition and the … of the content regulation is ambiguous and depends, among other things, on the cost effectiveness of advertisement and …

Persistent link: https://www.econbiz.de/10012897821

Pharmaceutical Industry, Drug Quality and Regulation : Evidence from Us and Italy

Atella, Vincenzo - 2008

This paper examines the relationship between drug price and drug quality and how it varies across two of the most common regulatory regimes in the pharmaceutical market: minimum efficacy standards (MES) and a mix of minimum efficacy standards and price control mechanisms (MES+PC). Through a...

Persistent link: https://www.econbiz.de/10012768128

Regulatory Review Time and Pharmaceutical R&D

Chorniy, Anna - 2019

In the United States, all newly developed drugs undergo a lengthy review process conducted by the Federal Food and Drug Administration (FDA). These regulatory delays are costly for drug manufacturers and patients. We collected data on review times of drugs approved between 1999 and 2005 and...

Persistent link: https://www.econbiz.de/10012865204

Does EU Anti-Corruption Regulation Work? The Case of Pharmaceutical Industry

Almici, Alex - 2016

against this widespread phenomenon. This study aims at verifying the European regulation's contribution in combating … corruption occurring in the pharmaceutical sector; in this regard, the main results underline some limits of regulation as well … regulation implying potential risk of no-compliance. The most relevant strength factors relate to the preventive policy …

Persistent link: https://www.econbiz.de/10012977364

Manufacturing and Regulatory Barriers to Generic Drug Competition : A Structural Model Approach

Wang, Yixin (Iris) - 2020

Understanding the drivers of market concentration in the generic pharmaceutical industry is essential to guaranteeing the availability of low-cost generics. In this paper, we develop a structural model to capture the multiple determinants governing manufacturers' entry decisions; in particular,...

Persistent link: https://www.econbiz.de/10012852626

How Do Opioid Prescribing Restrictions Affect Pharmaceutical Promotion? Lessons from the Mandatory Access Prescription Drug Monitoring Programs

Nguyen, Thuy Dieu - 2019

Prior work considers effects of prescribing restrictions on opioid use but not upstream implications for pharmaceutical marketing activities, despite the inordinate role many believe marketing played in the crisis. Our study proposes a stylized model of pharmaceutical payments and investigates...

Persistent link: https://www.econbiz.de/10012861727

The Faces of Regulation Profit and Price Regulation of the UK Pharmaceutical Industry after the 1998 Competition Act

Mestre-Ferrandiz, Jorge - 2015

pharmaceutical industry. It does so in the context of a discussion of “ex ante” versus “ex post”approaches to regulation. This refers … to the balance of reliance in a market on competition, sector specific regulation, and general competition law to deliver … Pharmaceutical Price Regulation Scheme (PPRS) as part of its review of government procurement arrangements in key sectors of the …

Persistent link: https://www.econbiz.de/10013017898

Comparative and Relative Effectiveness : A Challenge for Health Systems, Regulators, or Pharmaceutical Companies?

Towse, Adrian - 2015

Looking at how well drugs work in routine clinical practice, rather than only in experimental randomised controlled clinical trials (RCTs), is increasingly seen as essential for a proper assessment of both net benefit (health gain minus harm and value (net benefit minus net cost). Establishing...

Persistent link: https://www.econbiz.de/10013018440

Generic competition and price regulation in pharmaceuticals : evidence from the European Union

Tuncay, Berna - In: Dynamic optics in economics : quantitative, …, (pp. 221-240). 2020

Persistent link: https://www.econbiz.de/10013040759